ESMO临床实践指南骨髓增生异常综合征的诊断治.docx
- 文档编号:28547478
- 上传时间:2023-07-18
- 格式:DOCX
- 页数:12
- 大小:1,004.44KB
ESMO临床实践指南骨髓增生异常综合征的诊断治.docx
《ESMO临床实践指南骨髓增生异常综合征的诊断治.docx》由会员分享,可在线阅读,更多相关《ESMO临床实践指南骨髓增生异常综合征的诊断治.docx(12页珍藏版)》请在冰豆网上搜索。
ESMO临床实践指南骨髓增生异常综合征的诊断治
AnnalsofOncology17.RigolinGM,CuneoA,RobertiMGetal.Exposuretomyelotoxicagentsandmyelodysplasia:
case-controlstudyandcorrelationwithclinicobiologicalfindings.BrJHaematol1998;103:
189–197.18.ValentP,HornyHP,BennetJMetal.Definitionsandstandardsinthediagnosisandtreatmentofthemyelodysplasticsyndromes:
consensusstatementsandreportfromaworkingconference.LeukRes2007;31:
727–736.19.JaffeES,HarrisNL,SteinHetal.(eds.WorldHealthOrganizationClassificationofTumours,PathologyandGeneticsofHaematopoieticandLymphoidTissues.Lyon:
IARCPress,2008,pp.75–104.20.ValentP,HornyHP.MinimaldiagnosticcriteriaformyelodysplasticsyndromesandseparationfromICUSandIDUS:
updateandopenquestions.EurJClinInvest2009;39:
548–553.21.GermingU,HildebrandtB,PfeilstöckerMetal.Refinementoftheinternationalprognosticscoringsystem(IPSSbyincludingLDHasanadditionalprognosticvariabletoimproveriskassessmentinpatientswithprimarymyelodysplasticsyndromes(MDS.Leukemia2005;19:
2223–2231.22.HaaseD,GermingU,SchanzJetal.NewinsightsintotheprognosticimpactofthekaryotypeinMDSandcorrelationwithsubtypes:
evidencefromacoredatasetof2124patients.Blood2007;110:
4385–4395.23.MohamedaliA,GäkenJ,TwineNAetal.Prevalenceandprognosticsignificanceofallelicimbalancebysingle-nucleotidepolymorphismanalysisinlow-riskmyelodysplasticsyndromes.Blood2007;110:
3365–3373.24.BoultwoodJ,WainscoatJS.GenesilencingbyDNAmethylationinhaematologicalmalignancies.BrJHaematol2007;138:
3–11.25.ShafferLG,McGowan-JordanJ,SchmidM(eds.ISCN:
anInternationalSystemforHumanCytogeneticNomenclature.Basel:
S.Karger,2013.26.HaferlachC,RiederH,LillingtonDMetal.Proposalsforstandardizedprotocolsforcytogeneticanalysesofacuteleukemias,chroniclymphocyticleukemia,chronicmyeloidleukemia,chronicmyeloproliferativedisorders,andmyelodysplasticsyndromes.GenesChromosomesCancer2007;46:
494–499.27.SoléF,LuñoE,SanzoCetal.Identificationofnovelcytogeneticmarkerswithprognosticsignificanceinaseriesof968patientswithprimarymyelodysplasticsyndromes.Haematologica2005;90:
1168–1178.28.SchanzJ,SteidlC,FonatschCetal.Coalescedmulticentricanalysisof2,351patientswithmyelodysplasticsyndromesindicatesanunderestimationofpoorriskcytogeneticsofmyelodysplasticsyndromesintheinternationalprognosticscoringsystem.JClinOncol2011;29:
1963–1970.29.ValcárcelD,AdemàV,SoléFetal.Complex,notmonosomal,karyotypeisthecytogeneticmarkerofpoorestprognosisinpatientswithprimarymyelodysplasticsyndrome.JClinOncol2013;31:
916–922.30.SchanzJ,TüchlerH,SoléFetal.MonosomalkaryotypeinMDS:
explainingthepoorprognosis?
Leukemia2013;27:
1988–1995.31.YoshidaK,SanadaM,ShiraishiYetal.Frequentpathwaymutationsofsplicingmachineryinmyelodysplasia.Nature2011;478:
64–69.32.PapaemmanuilE,GerstungM,MalcovatiLetal.Clinicalandbiologicalimplicationsofdrivermutationsinmyelodysplasticsyndromes.Blood2013;122:
3616–3627.33.WestersTM,IrelandR,KernWetal.Standardizationofflowcytometryinmyelodysplasticsyndromes:
areportfromaninternationalconsortiumandtheEuropeanLeukemiaNetWorkingGroup.Leukemia2012;26:
1730–1741.34.SwerdlowSH,CampoE,HarrisNLetal.(eds.WHOClassificationofTumoursofHaematopoieticandLymphoidTissues,4thedition.Lyon:
IARCPress,2008.35.TefferiA,VardimanJW.Myelodysplasticsyndromes.NEnglJMed2009;361:
1872–1885.36.SanzGF,SanzMA,VallespiTetal.Tworegressionmodelsandascoringsystemforpredictingsurvivalandplanningtreatmentinmyelodysplasticsyndromes:
amultivariateanalysisofprognosticfactorsin370patients.Blood1989;74:
395–408.37.VosoMT,FenuS,LatagliataRetal.RevisedInternationalPrognosticScoringSystem(IPSSpredictssurvivalandleukemicevolutionofmyelodysplasticsyndromessignificantlybetterthanIPSSandWHOPrognosticScoringSystem:
validationbytheGruppoRomanoMielodisplasieItalianRegionalDatabase.JClinOncol2013;31:
2671–2677.clinicalpracticeguidelines38.MalcovatiL,Hellström-LindbergE,BowenDetal.Diagnosisandtreatmentofprimarymyelodysplasticsyndromesinadults:
recommendationsfromtheEuropeanLeukemiaNet.Blood2013;122:
2943–2964.39.DellaPortaMG,MalcovatiL,BoveriEetal.ClinicalrelevanceofbonemarrowfibrosisandCD34-positivecellclustersinprimarymyelodysplasticsyndromes.JClinOncol2009;27:
754–762.40.MalcovatiL,GermingU,KuendgenAetal.Time-dependentprognosticscoringsystemforpredictingsurvivalandleukemicevolutioninmyelodysplasticsyndromes.JClinOncol2007;25:
3503–3510.41.EsteyEH,ThallPF,CortesJEetal.Comparisonofidarubicin+ara-C-,fludarabine+ara-C-,andtopotecan+ara-C-basedregimensintreatmentofnewlydiagnosedacutemyeloidleukemia,refractoryanaemiawithexcessblastsintransformation,orrefractoryanaemiawithexcessblasts.Blood2001;98:
3575–3583.42.FenauxP,MuftiGJ,Hellström-LindbergEetal.Efficacyofazacitidinecomparedwiththatofconventionalcareregimensinthetreatmentofhigher-riskmyelodysplasticsyndromes:
arandomised,open-label,phaseIIIstudy.LancetOncol2009;10:
223–232.43.GurionR,VidalL,Gafter-GviliAetal.5-azacitidineprolongsoverallsurvivalinpatientswithmyelodysplasticsyndrome—asystematicreviewandmeta-analysis.Haematologica2010;95:
303–310.44.GoreSD,FenauxP,SantiniVetal.Amultivariateanalysisoftherelationshipbetweenresponseandsurvivalamongpatientswithhigher-riskmyelodysplasticsyndromestreatedwithinazacitidineorconventionalcareregimensintherandomizedAZA-001trial.Haematologica2013;98:
1067–1072.45.KnippS,HildebrandB,KündgenAetal.Intensivechemotherapyisnotrecommendedforpatientsaged>60yearswhohavemyelodysplasticsyndromesoracutemyeloidleukemiawithhigh-riskkaryotypes.Cancer2007;110:
345–352.46.KantarijanHM,O’BrienS,HuangXetal.Survivaladvantagewithdecitabineversusintensivechemotherapyinpatientswithhigherriskmyelodysplasticsyndrome:
comparisonwithhistoricalexperience.Cancer2007;109:
1133–1137.47.ZwierzinqH,SuciuS,Loeffler-RaggJetal.Low-dosecytosinearabinoside(LD-AraCvsLD-AraCplusgranulocyte/macrophagecolonystimulatingfactorvsLD-AraCplusInterleukin-3formyelodysplasticsyndromepatientswithahighriskofdevelopingacuteleukemia:
finalresultsofarandomizedphaseIIIstudy(06903oftheEORTCLeukemiaCooperativeGroup.Leukemia2005;19:
1929–1933.48.ChesonBD,SimonR.Low-doseara-Cinacutenonlymphocyticleukemiaandmyelodysplasticsyndromes:
areviewof20years’experience.SeminOncol1987;14(2Suppl1:
126–133.49.FenauxP,LaiJL,GardinCetal.CytogeneticsareapredictivefactorofresponsetolowdoseAra-Cinacutemyelogenousleukemia(AMLintheelderly.Leukemia1990;4:
312.50.PrebetT,GoreSD,EsterniBetal.Outcomeofhigh-riskmyelodysplasticsyndromeafterazacitidinetreatmentfailure.JClinOncol2011;29:
3322–3327.51.BrandR,PutterH,vanBiezenAetal.Comparisonofallogeneicstemcelltransplantationandnon-transplantapproachesinelderlypatientswithadvancedmyelodysplasticsyndrome:
optimalstatisticalapproachesandacriticalappraisalofclinicalresultsusingnon-randomizeddata.PLoSOne2013;8:
e74368.52.VaughnJE,ScottBL,DeegHJ.Transplantationformyelodysplasticsyndromes2013.CurrOpinHematol2013;20:
494–500.53.GuardiolaP,RundeV,BacigalupoAetal.Retrospectivecomparisonofbonemarrowandgranulocytecolony-stimulatingfactor-mobilizedperipheralbloodprogenitorcellsforallogeneicstemcelltransplantationusingHLAidenticalsiblingdonorsinmyelodysplasticsyndromes.Blood2002;99:
4370–4378.54.MittelmanM,OsterHS,HoffmanM,NeumannD.ThelowerriskMDSpatientatriskofrapidprogression.LeukRes2010;34:
1551–1555.55.BejarR,StevensonKE,CaugheyBAetal.Validationofaprognosticmodelandtheimpactofmutationsinpatientswithlower-riskmyelodysplasticsyndromes.JClinOncol2012;30:
3376–3382.56.KelaidiC,ParkS,SapenaRetal.Long-termoutcomeofanemiclower-riskmyelodysplasticsyndromeswithout5qdeletionrefractorytoorrelapsingaftererythropoiesis-stimulatingagents.Leukemia2013;27:
1283–1290.57.FenauxP,RoseC.Impactofironoverloadinmyelodysplasticsyndromes.BloodRev2009;23(Suppl1:
S15–S19.Downloadedfromhttp:
//annonc.oxfordjournals.org/byguestonSeptember16,2014Volume25|Supplement3|September2014doi:
10.1093/annonc/mdu180|iii
clinicalpracticeguidelines58.CrawfordJ,CellaD,CleelandCSetal.Relationshipbetweenchangesinhemoglobinlevelandqualityoflifeduringchemotherapyinanemiccancerpatientsreceivingepoetinalfatherapy.Cancer2002;95:
888–895.59.RoyNB,MyersonS,SchuhAHetal.Cardiacironoverloadintransfusiondependentpatientswithmyelodysplasticsyndromes.BrJHaematol2011;154:
521–524.60.ParkS,GrabarS,KelaidiCetal.PredictivefactorsofresponseandsurvivalinmyelodysplasticsyndrometreatedwitherythropoietinandG-CSF:
theGFMexperience.Blood2008;111:
574–582.61.JaderstenM,MalcovatiL,DybedalIetal.Erythropoietinandgranulocyte-colonystimulatingfactortreatmentassociatedwithimprovedsurvivalinmyelodysplasticsyndrome.JClinOncol2008;26:
3607–3613.62.GreenbergPL,SunZ,MillerKBetal.Treatmentofmyelodysplasticsyndromepatientswitherythropoietinwithorwithoutgranulocytecolonystimulatingfactor:
resultsofaprospectiverandomizedphase3trialbytheEasternCooperati
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- ESMO 临床 实践 指南 骨髓 增生 异常 综合征 诊断